Why is the Telix Pharmaceuticals (ASX:TLX) share price plummeting 13% today?

This biotech company is having a shocker to start the trading week.

| More on:
A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Telix Pharmaceuticals share price is down 13% on Monday
  • The company's December quarterly report revealed a 51% fall in cash reserves
  • It is also conducting a $175 million capital raise

The Telix Pharmaceuticals (ASX: TLX) share price is tumbling today amid the release of the company's December quarter results and a capital raise update.

The biotechnology company's shares are currently trading at $7.05, plunging 12.86% from the open.

Let's take a look at what might be weighing on investors minds today.

Why is the company's share price falling?

Telix provided results for its December quarter. The highlights include:

  • Cash reserves of $22.04 million, down 51.93% from $45.85 million in the previous quarter
  • Net operating outflows of $20.97 million with total operating outflows of $21.96 million, as forecasted
  • The company invested $6.96 million in research and clinical development
  • Cash inflows of $0.99 million

The company highlighted it had received regulatory approval from the US FDA for its lead prostate cancer imaging product Illuccix. This product also has regulatory approval in Australia. Telix is also working on distribution agreements in Europe.

Telix's capital raise announcement

Investors may also be reacting to the company's capital raise announcement.

Telix has successfully completed a $175 million institutional placement at $7.70 per new share. The company will also conduct a share purchase plan to raise a further $25 million.

The funds are being raised to help the company advance its products towards commercialisation. This includes its prostate cancer therapy clinical program and Targeted Alpha Therapy. The company is also launching its first commercial product Illuccix following US Food and Drug Agency approval.

Speaking on the announcement, CEO Dr Christian Behrenbruch said:

We are delighted with the level of support for the placement from new and existing investors.

Funds raised under the placement and SPP will provide the company with the financial resources to execute on the next phase of Telix's growth strategy.

We are particularly pleased to attract high quality, specialist investors to the register and would
like to welcome our new investors and thank our existing shareholders for their outstanding
support.

Telix cofounders Behrenbruch and Dr Andreas Kluge will also sell 2 million shares to coincide with the placement. This represents 8.1% of their total shares in the company. Both have pledged to the board they will not sell any further shares in the next 12 months.

Telix Pharmaceuticals share price recap

The Telix Pharmaceuticals share price has rocketed 55.9% in the past year. However, it has slipped 11% in the past month, down more than 18% in the past week alone.

Meanwhile, the broader S&P/ASX 200 Index (ASX: XJO) has returned roughly 5% over the past 12 months.

The company has a market capitalisation of around $2 billion based on its current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »